AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
4.740
-0.060 (-1.25%)
Apr 28, 2026, 4:00 PM EDT - Market closed
AN2 Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -35.17 | -51.32 | -64.73 | -40.96 | -21.54 | |
| Loss (Gain) From Sale of Investments | -1.07 | -3.28 | -2.86 | -0.69 | 0.05 | |
| Stock-Based Compensation | 6.25 | 8.34 | 8.41 | 4.39 | 0.97 | |
| Other Operating Activities | - | - | 0.05 | 0.08 | - | |
| Change in Accounts Payable | -0.3 | 0.64 | 0.55 | 2.5 | 0.42 | |
| Change in Other Net Operating Assets | 0.46 | -3.64 | 5.28 | 1.22 | -0.39 | |
| Operating Cash Flow | -29.83 | -49.26 | -53.29 | -33.46 | -20.48 | |
| Investment in Securities | 28.31 | 54.59 | -43.28 | -21.77 | -50.02 | |
| Investing Cash Flow | 28.31 | 54.59 | -43.28 | -21.77 | -50.02 | |
| Issuance of Common Stock | 0.11 | 0.37 | 84.99 | 70.37 | 0.01 | |
| Repurchase of Common Stock | - | - | - | -0.01 | - | |
| Other Financing Activities | - | - | - | - | -1.21 | |
| Financing Cash Flow | 0.11 | 0.37 | 84.99 | 70.36 | 78.54 | |
| Net Cash Flow | -1.41 | 5.7 | -11.57 | 15.12 | 8.03 | |
| Levered Free Cash Flow | -18.38 | -29 | -28.85 | -19.3 | -11.96 | |
| Unlevered Free Cash Flow | -18.38 | -29 | -28.85 | -19.3 | -11.96 | |
| Change in Working Capital | 0.16 | -3 | 5.83 | 3.72 | 0.03 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.